



**Abgenix Receives Milestone Payment from Human Genome Sciences for Advancement of CCR5 Antibody Product Candidate; Ninth XenoMouse Antibody Advances to the Clinical Phase**

FREMONT, Calif.--(BUSINESS WIRE)--Jan. 10, 2005--Abgenix, Inc. (Nasdaq: ABGX) announced today that it has received a milestone payment triggered by Human Genome Sciences' filing of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for a fully human monoclonal antibody to the CCR5 receptor (CCR5 mAb) created using Abgenix's proprietary XenoMouse(R) technology.

"Human Genome Sciences is the fourth of our technology licensing partners to advance an antibody from our proprietary technology to the clinical stage," said Bill Ringo, president and chief executive officer of Abgenix. "We are pleased to see the continued progress of these types of collaborations, which provide potential future milestones and revenues to Abgenix."

The CCR5 receptor is a co-receptor on the cell surface that, together with CD4, mediates the binding of HIV and its entry cell. CCR5 mAb is designed to bind to and block the CCR5 receptor, which would prevent the entry of HIV into immune system cells. Preclinical results show that CCR5 mAb binds to the CCR5 receptor and can neutralize HIV replication in vitro.

Human Genome Sciences generated the CCR5 mAb using the Abgenix XenoMouse(R) technology. In May 2003, Abgenix granted Human Genome Sciences a license to develop and commercialize the CCR5 mAb. Under the terms of the agreement Abgenix may receive additional clinical development milestone payments and royalties on any future product sales. CCR5 mAb is manufactured by Human Genome Sciences.

**About Abgenix**

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at [www.abgenix.com](http://www.abgenix.com).

Statements made in this press release about Abgenix's technologies, product development activities, including clinical trials and clinical trial results, collaborative arrangements, process sciences and manufacturing activities, other than statements of historical fact, and about its potential revenues and the achievement of milestone or similar payments, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, product manufacturing, regulatory approval processes and meeting requirements for regulatory approval, competitive products and services, current and future capital requirements, the extent and breadth of Abgenix's patent portfolio, and other factors set forth in Abgenix's public filings with the Securities and Exchange Commission including Abgenix's quarterly report on Form 10-Q for the quarter ended September 30, 2004 and annual report on Form 10-K for the year ended December 31, 2003. Abgenix is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements.

CONTACT: Abgenix, Inc.  
Ami Knoefler, 510-284-6350 or 510-284-6605  
(Senior Director, Corporate Communications and IR)

SOURCE: Abgenix, Inc.